Lubomir Minarik

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Redox-dependent protein S-glutathionylation governs azacitidine sensitivity and resistance in AML.

Redox-dependent protein S-glutathionylation governs azacitidine sensitivity and resistance in AML.

Journal: Redox biology
Published: October 21, 2025

Real-World Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia: Insights From the Czech Republic.

Real-World Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia: Insights From the Czech Republic.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 14, 2025

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML.

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML.

Journal: Frontiers in oncology
Published: April 09, 2024

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa.

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa.

Journal: Frontiers in oncology
Published: March 09, 2024

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.

Journal: Blood cancer journal
Published: April 14, 2022

Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.

Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.

Journal: International journal of molecular sciences
Published: December 21, 2021

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.

Journal: Cells
Published: December 15, 2021

Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry.

Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry.

Journal: Folia biologica
Published: June 09, 2020

NQO1*2 polymorphism predicts overall survival in MDS patients.

NQO1*2 polymorphism predicts overall survival in MDS patients.

Journal: British journal of haematology
Published: January 25, 2018

Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).

Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).

Journal: Leukemia research
Published: December 10, 2017

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.

Journal: Blood cancer journal
Published: July 22, 2017

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.

Journal: Oncotarget
Published: March 29, 2017
Showing 1-12 of 12

Last Updated: 09/26/2026